PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
3.08%
ROE exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.36%. Joel Greenblatt would check if high returns reflect a sustainable advantage.
2.61%
ROA of 2.61% while Drug Manufacturers - Specialty & Generic median is zero. Peter Lynch would see if minimal profitability can widen over time.
-1.08%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is 0.13%. Seth Klarman would investigate whether a turnaround is viable.
27.61%
Gross margin below 50% of Drug Manufacturers - Specialty & Generic median of 57.53%. Jim Chanos would suspect flawed products or pricing.
-99.48%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for a path to operational turnaround.
252.79%
Net margin of 252.79% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss would examine if modest profitability can expand.